PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, teeing the biotech to seek ...

Nineteen states and the District of Columbia have filed a new lawsuit against HHS Secretary Robert F. Kennedy Jr. in hopes of ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Biomea Fusion is following through on a New Year’s resolution to become a metabolic-focused company. | Biomea Fusion is ...

Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be ...

Deerfield Management has unveiled the third installment of its healthcare innovations fund, earmarking more than $600 million ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

The Jewel wearable cardioverter defibrillator system can be worn during sleep and showers, with its low-profile and ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope ...